Department of Pediatric, Section of Pediatric Gastroenterology, Hepatology, and Nutrition, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Department of Pediatric, Section of Pediatric Gastroenterology, Burjeel Specialty Hospital, Sharjah, United Arab Emirates.
Saudi J Gastroenterol. 2022 Nov-Dec;28(6):448-455. doi: 10.4103/sjg.sjg_162_22.
Inflammatory bowel disease (IBD) is a chronic gastrointestinal tract disorder characterized by periods of exacerbations and remissions that affect multiple aspects of a pediatric patient's quality of life. The purpose of this study is to describe the health-related quality of life of Saudi pediatric IBD patients and to determine the influencing factors which can affect it.
This is a single center cross-sectional descriptive study, conducted between December 2019 and December 2021. Patients aged between 9 and 16 years diagnosed with IBD were included; IMPACT III quality of life questionnaire was used.
Thirty-eight patients participated in the study, 57.9 % being male, with a mean age of 12.48 ± 2.72 years, and 55.3 % of patients were diagnosed with Crohn's disease (CD). The most frequent medications were aminosalicylic acids derivatives, followed by immune-modulators and biologics. The IMPACT III quality of life questionnaire has shown lower scores in IBD patients in comparison to healthy control groups. Patients with active disease have lower total and sub-domain scores than patients with inactive disease. We found no correlation between health-related quality of life (HrQOL) and the number of medications used, disease duration, or gender.
Pediatric IBD patients have significantly lower HrQOL scores than healthy children. Disease activity was found to be a predictor for poor HrQOL outcome.
炎症性肠病（IBD）是一种慢性胃肠道疾病，其特征是发作和缓解期交替出现，影响儿童患者生活质量的多个方面。本研究旨在描述沙特儿科 IBD 患者的健康相关生活质量，并确定影响其生活质量的因素。
这是一项单中心横断面描述性研究，于 2019 年 12 月至 2021 年 12 月进行。纳入年龄在 9 至 16 岁之间、被诊断为 IBD 的患者；使用了 IMPACT III 生活质量问卷。
38 名患者参与了研究，其中 57.9%为男性，平均年龄为 12.48±2.72 岁，55.3%的患者被诊断为克罗恩病（CD）。最常用的药物是氨基水杨酸盐衍生物，其次是免疫调节剂和生物制剂。与健康对照组相比，IBD 患者的 IMPACT III 生活质量问卷评分较低。处于活动期的患者总评分和各子域评分均低于非活动期患者。我们未发现生活质量（HrQOL）与使用药物数量、疾病持续时间或性别之间存在相关性。
儿科 IBD 患者的生活质量评分明显低于健康儿童。疾病活动度是生活质量较差的预测因素。
